Low carbohydrate/high-fat diet attenuates cardiac hypertrophy, remodeling, and altered gene expression in

Isidore C Okere1, Martin E Young, Tracy A McElfresh

  • 1Department of Physiology and Biophysics, Case Western Reserve University, Cleveland, OH 44106-4970, USA.

Insights

High-fat diets may protect against hypertension-induced heart changes. Increased dietary lipids reduced cardiac growth, remodeling, and dysfunction in rats, suggesting a protective effect against cardiovascular stress.

Area of Science:

  • Cardiovascular Physiology
  • Nutritional Science
  • Molecular Biology

Background:

  • The impact of dietary fat on cardiac remodeling during hypertension remains unclear.
  • Hypertension commonly leads to left ventricular hypertrophy and dysfunction.

Purpose of the Study:

  • To investigate how high-fat versus low-fat diets affect left ventricular hypertrophy and remodeling in response to hypertension.
  • To assess the influence of diet on molecular markers and contractile function in hypertensive hearts.

Main Methods:

  • Dahl salt-sensitive rats were fed low-fat (10%) or high-fat (60%) diets with low or high salt for 12 weeks.
  • Cardiac structure, function, and molecular markers (e.g., atrial natriuretic factor mRNA) were analyzed.
  • Mitochondrial enzyme activities (citrate synthase, acyl-coenzyme A dehydrogenase) were measured.

Main Results:

  • High-salt feeding induced similar hypertension (approx. 190 mm Hg) in both diet groups.
  • Low-fat diet exacerbated hypertension-induced left ventricular hypertrophy, reduced ejection fraction, and increased cardiac remodeling markers.
  • High-fat diet significantly attenuated these adverse cardiac effects, including molecular alterations and mitochondrial dysfunction.

Conclusions:

  • Increased dietary lipid intake mitigates cardiac hypertrophy, remodeling, and contractile dysfunction caused by hypertension.
  • Dietary fat composition plays a crucial role in modulating the cardiac response to hypertensive stimuli.
  • High-fat feeding may offer a protective strategy against hypertensive heart disease progression.

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Cellular Adaptation II: Hypertrophy01:26

Cellular Adaptation II: Hypertrophy

Hypertrophy is the increase in the size of individual cells, resulting in the enlargement of a tissue or organ. Unlike hyperplasia, which involves an increase in cell number, hypertrophy is characterized by an increase in cell volume. This process often occurs in response to higher functional demand or hormonal stimulation, leading to the production of more structural proteins and organelles, thereby enhancing the cells' work capacity.There are two primary types of hypertrophy: physiological...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...